Springbok Capital Management »

Aerovate Therapeutics shares owned by Springbok Capital Management

Quarter-by-quarter ownership of Aerovate Therapeutics (AVTE) shares owned by Springbok Capital Management from 13F filings

Historical chart of Springbok Capital Management investment in Aerovate Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Aerovate Therapeutics held by Springbok Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Aerovate Therapeutics by Springbok Capital Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $612k 21k 29.57

More positions owned by Springbok Capital Management

Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Ishares Tr Russell 2000 Etf Put Option (IWM)
NVIDIA Corporation (NVDA)
Spdr Gold Tr Gold Shs (GLD)
Ishares Tr 20 Yr Tr Bd Etf Put Option (TLT)
Brighthouse Finl (BHF)
Bio Rad Labs Cl A (BIO)
Baidu Spon Adr Rep A (BIDU)
Pioneer Natural Resources (PXD)
Hess (HES)
Microsoft Corporation (MSFT)
Overstock (BYON)
Netease Sponsored Ads (NTES)
Amazon (AMZN)
Alphabet Cap Stk Cl A (GOOGL)

View all positions for Springbok Capital Management

Top funds holding Aerovate Therapeutics

RA Capital Management
Sofinnova Ventures
TCG Crossover Management
Atlas Venture Life Science Advisors
Baker Bros. Advisors
Frazier Life Sciences Management
Cormorant Asset Management
Dr. Jeffrey R. Jay, M.D.
Driehaus Capital Management
BlackRock
Vanguard Group
OrbiMed Advisors
FMR
Eventide Asset Management
Octagon Capital Advisors

View all funds holding Aerovate Therapeutics